Chong purchased 400,000 shares at 2.2 cents per share, increasing her total number of securities held in the company to more than 3.91 million shares and 77.09 million options.
CheckVacc data published in prestigious journal
In February Imugene had preclinical data and results for its licensed oncolytic virotherapy CheckVacc published in the prestigious Journal of American College of Surgeons.
Peritoneal carcinomatosis (PC) from pancreatic ductal adenocarcinoma (PDAC) is fatal and Imugene’s preclinical study presents an effective treatment against PDAC PC employing a novel oncolytic viral agent, CheckVacc.
While the paper details the results seen in pancreatic cancer, CheckVacc will initially be tested in patients suffering Triple-Negative Breast Cancer (TNBC), where equally important preclinical data has been collected.